Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 8/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759853 | 0.94 | NPSR1 (0.56) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3429942 | 0.94 | TSHR (0.57) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3430299 | 0.93 | USP2 (0.55) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3427905 | 0.92 | MAPT (0.56) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3430664 | 0.92 | RAB9A (0.56) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3432551 | 0.91 | ALDH1A1 (0.57) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL30448176 | 0.91 | ELANE (0.57) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL28363291 | 0.91 | ELANE (0.57) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3432147 | 0.90 | USP2 (0.52) | RAB9ANPC1USP2TSHRNPSR1 | |
| SCHEMBL3430287 | 0.90 | PTGER4 (0.57) | RAB9ANPC1USP2TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | claimed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | claimed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | claimed |
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | RAB9A 2878/4885NPC1 2272/4885USP2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.